Patient-reported neuropathy and taxane-associated symptoms in a phase 3 trial of nab-paclitaxel plus carboplatin versus solvent-based paclitaxel plus carboplatin for advanced non-small-cell lung cancer

Journal of Thoracic Oncology

Volumn 9, Issue 1, 2014, Pages 83-90

  Hirsh, Vera ^a   Okamoto, Isamu ^b   Hon, Jeremy K ^c   Page, Ray D ^d   Orsini, James ^e   Sakai, Hiroshi ^f   Zhang, Hui ^g   Renschler, Markus F ^g   Socinski, Mark A ^h  

^a MCGILL UNIVERSITY   (Canada)

^b KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Clearview Cancer Institute   (United States)

^d Center for Cancer and Blood Disorders   (United States)

^e Essex Oncology of New Jersey   (United States)

^f SAITAMA CANCER CENTER   (Japan)

^g CELGENE CORPORATION   (United States)

^h UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Functional Assessment of Cancer Therapy Taxane; Nab Paclitaxel; Non small cell lung cancer; Peripheral neuropathy; Solvent based paclitaxel

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ADVANCED CANCER; AGED; ANEMIA; ARTHRALGIA; ARTICLE; BLOATING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FOOT PAIN; HAND EDEMA; HAND PAIN; HAND PARESTHESIA; HEARING IMPAIRMENT; HUMAN; LEG EDEMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NATIONAL HEALTH ORGANIZATION; NEUROPATHIC PAIN; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; STATISTICAL SIGNIFICANCE; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; AGED; ALBUMINS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRIDGED COMPOUNDS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; PARANEOPLASTIC POLYNEUROPATHY; QUALITY OF LIFE; TAXOIDS;

EID: 84891770468     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000011     Document Type: Article

References (37)

1. The Stage IV NSCLC treatment [National Cancer Institute Web site]. Available at: Http://www.cancer.gov/cancertopics/pdq/treatment/nonsmall- cell-lung/healthprofessional/page11. Accessed March 2, 2012
2. Socinski MA. The role of chemotherapy in the treatment of unresectable stage III and IV nonsmall cell lung cancer. Respir Care Clin N Am 2003;9:207-236
3. Cella D, Peterman A, Hudgens S, Webster K, Socinski MA. Measuring the side effects of taxane therapy in oncology: The Functional Assessment of Cancer Therapy-Taxane (FACT-Taxane). Cancer 2003;98:822-831
4. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216
5. Silvestri G, Pritchard R, Welch HG. Preferences for chemotherapy in patients with advanced non-small cell lung cancer: Descriptive study based on scripted interviews. BMJ 1998;317:771-775
6. McPherson CJ, Wilson KG, Lobchuk MM, Brajtman S. Self-perceived burden to others: Patient and family caregiver correlates. J Palliat Care 2007;23:135-142
7. McPherson CJ, Wilson KG, Murray MA. Feeling like a burden; exploring the perspectives of patients at the end of life. Soc Sci Med 2007;64:417-427
8. Johnson JO, Sulmasy DP, Nolan MT. Patients experiences of being a burden on family in terminal illness. J Hosp Palliat Nurs 2007;9:264-269
9. de Marinis F, Pereira JR, Fossella F, et al. Lung cancer symptom scale outcomes in relation to standard efficacy measures: An analysis of the phase III study of pemetrexed versus docetaxel in advanced non-small cell lung cancer. J Thorac Oncol 2008;3:30-36
10. Mohan A, Singh P, Kumar S, et al. Effect of change in symptoms, respiratory status, nutritional profile and quality of life on response to treatment for advanced non-small cell lung cancer. Asian Pac J Cancer Prev 2008;9:557-562
11. Tanvetyanon T, Soares HP, Djulbegovic B, Jacobsen PB, Bepler G. A systematic review of quality of life associated with standard chemotherapy regimens for advanced non-small cell lung cancer. J Thorac Oncol 2007;2:1091-1097
12. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Version 2.2014. Available at; http://www.nccn.org/professionals/physician-gls/pdf/nscl.pdf. Accessed December 23, 2012
13. Taxol (paclitaxel) [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2011
14. Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005;23:7794-7803
15. Gardner ER, Dahut WL, Scripture CD, et al. Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel. Clin Cancer Res 2008;14:4200-4205
16. Desai N, Trieu V, Yao Z, et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of Cremophorfree, albumin-bound paclitaxel, ABI-007, compared with Cremophorbased paclitaxel. Clin Cancer Res 2006;12:1317-1324
17. Gradishar WJ, Krasnojon D, Cheporov S, et al. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol 2009;27:3611-3619
18. Green MR, Manikhas GM, Orlov S, et al. Abraxane, a novel Cremophorfree, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann Oncol 2006;17:1263-1268
19. Rizvi NA, Riely GJ, Azzoli CG, et al. Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer. J Clin Oncol 2008;26; 639-643
20. Socinski MA, Manikhas GM, Stroyakovsky DL, et al. A dose finding study of weekly and every-3-week nab-paclitaxel followed by carboplatin as first-line therapy in patients with advanced non-small cell lung cancer. J Thorac Oncol 2010;5:852-861
21. Socinski MA, Bondarenko I, Karaseva NA, et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: Final results of a phase III trial. J Clin Oncol 2012;30:2055-2062
22. Belani CP, Ramalingam S, Perry MC, et al. Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer. J Clin Oncol 2008;26:468-473
23. Gao G, Chu H, Zhao L, Gui T, Xu Q, Shi J. A meta-analysis of paclitaxelbased chemotherapies administered once every week compared with once every 3 weeks first-line treatment of advanced non-small-cell lung cancer. Lung Cancer 2012;76:380-386
24. Abraxane for Injectable Suspension (paclitaxel particles for injectable suspension) (albumin-bound) [package insert]. Summit, NJ: Celgene Corporation; 2012
25. Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy scale: Development and validation of the general measure. J Clin Oncol 1993;11:570-579
26. van Warmerdam LJ, Rodenhuis S, ten Bokkel Huinink WW, Maes RA, Beijnen JH. The use of the Calvert formula to determine the optimal carboplatin dosage. J Cancer Res Clin Oncol 1995;121:478-486
27. Good clinical practice research guidelines reviewed, emphasis given to responsibilities of investigators: Second article in a series. J Oncol Pract 2008;4:233-235
28. Gradishar WJ, Krasnojon D, Cheporov S, et al. Phase II trial of nab-paclitaxel compared with docetaxel as first-line chemotherapy in patients with metastatic breast cancer: Final analysis of overall survival. Clin Breast Cancer 2012;12:313-321
29. Pachman DR, Barton DL, Watson JC, Loprinzi CL. Chemotherapyinduced peripheral neuropathy: Prevention and treatment. Clin Pharmacol Ther 2011;90:377-387
30. Rowinsky EK, Chaudhry V, Cornblath DR, et al. Neurotoxicity of Taxol. J Natl Cancer Inst Monogr 1993;(15):107-115
31. Rivera E, Mejia JA, Arun BK, et al. Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer. Cancer 2008;112:1455-1461
32. Cortes J, Saura C. Nanoparticle albumin-bound (nab)-paclitaxel: Improving efficacy and tolerability by targeted drug delivery in metastatic breast cancer. EJC Supplements. 2010;8(1):1-10.33
33. Bristol-Myers Squibb Company (Ed). Paraplatin (carboplatin) [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2004
34. Taxotere (docetaxel) [package insert]. Bridgewater, NJ: Sanofi-Aventis US LLC; 2010
35. Sarafraz M, Ahmadi K. Paraclinical evaluation of side-effects of taxanes on auditory system. Acta Otorhinolaryngol Ital 2008;28:239-242
36. Pennell NA. Selection of chemotherapy for patients with advanced non-small cell lung cancer. Cleve Clin J Med. 2012;79(suppl 1); eS46-eS50
37. Hirsh V. Review of the treatment of metastatic non small cell lung carcinoma; a practical approach. World J Clin Oncol 2011;2:262-271